Eli Lilly and (NYSE:LLY) Reaches New 52-Week High at $447.51

Shares of Eli Lilly and Company (NYSE:LLY – Get Rating) reached a new 52-week high on Friday . The stock traded as high as $447.51 and last traded at $442.53, with a volume of 944266 shares. The stock had previously closed at $437.89.

Analysts Set New Price Targets

Several research analysts have recently weighed in on LLY shares. Wells Fargo & Company increased their price target on Eli Lilly and from $375.00 to $440.00 in a research note on Friday, April 28th. Credit Suisse Group increased their price target on Eli Lilly and from $420.00 to $490.00 in a research note on Thursday, May 4th. SVB Securities raised their target price on Eli Lilly and from $410.00 to $458.00 in a research note on Monday, May 1st. Cantor Fitzgerald raised their target price on Eli Lilly and from $432.00 to $485.00 in a research note on Friday, April 28th. Finally, UBS Group raised their target price on Eli Lilly and from $438.00 to $447.00 in a research note on Friday, April 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $415.75.

Eli Lilly and Trading Up 1.0 %

The company has a market capitalization of $419.94 billion, a PE ratio of 70.33, a PEG ratio of 2.33 and a beta of 0.37. The company has a current ratio of 1.30, a quick ratio of 1.02 and a debt-to-equity ratio of 1.67. The stock has a fifty day moving average of $378.15 and a two-hundred day moving average of $360.18.

Eli Lilly and (NYSE:LLY – Get Rating) last posted its quarterly earnings results on Thursday, April 27th. The company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.73 by ($0.11). Eli Lilly and had a return on equity of 61.42% and a net margin of 20.54%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.87 billion. During the same quarter in the previous year, the business earned $2.62 earnings per share. Eli Lilly and’s revenue was down 10.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 8.78 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 9th. Investors of record on Monday, May 15th will be given a dividend of $1.13 per share. The ex-dividend date is Friday, May 12th. This represents a $4.52 annualized dividend and a yield of 1.02%. Eli Lilly and’s payout ratio is 71.86%.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $435.29, for a total value of $261,174.00. Following the sale, the chief accounting officer now directly owns 5,978 shares in the company, valued at approximately $2,602,163.62. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $435.29, for a total value of $261,174.00. Following the sale, the chief accounting officer now directly owns 5,978 shares in the company, valued at approximately $2,602,163.62. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, March 24th. The shares were sold at an average price of $335.82, for a total value of $67,164,000.00. Following the sale, the insider now owns 102,748,810 shares in the company, valued at $34,505,105,374.20. The disclosure for this sale can be found here. Insiders have sold a total of 1,109,251 shares of company stock worth $411,295,505 in the last ninety days. 0.13% of the stock is owned by insiders.

Institutional Investors Weigh In On Eli Lilly and

Several hedge funds have recently made changes to their positions in the company. Y.D. More Investments Ltd purchased a new position in Eli Lilly and during the fourth quarter valued at $26,000. Silicon Valley Capital Partners purchased a new position in Eli Lilly and during the first quarter valued at $25,000. Bogart Wealth LLC raised its stake in Eli Lilly and by 193.3% during the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after buying an additional 58 shares during the last quarter. Destiny Wealth Partners LLC raised its stake in Eli Lilly and by 97.8% during the fourth quarter. Destiny Wealth Partners LLC now owns 91 shares of the company’s stock valued at $33,000 after buying an additional 45 shares during the last quarter. Finally, Laffer Tengler Investments purchased a new position in Eli Lilly and during the first quarter valued at $33,000. 82.13% of the stock is currently owned by institutional investors.

About Eli Lilly and

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.